Intrahepatic Stem Cell Therapy

Intrahepatic stem cell therapy is a promising approach for treating end-stage liver disease. When liver disease reaches its advanced stages, mortality rates rise significantly. In this context, cell therapy has emerged as a potential solution.

Most cases of liver cirrhosis, despite the cause, progress from liver fibrosis to an irreversible final stage: liver cirrhosis. Liver injury can be caused by several factors, such as viral infection (hepatitis B or hepatitis C), autoimmune liver disease (autoimmune hepatitis), drug-induced liver damage, or sustained alcohol abuse. Currently, there is not an effective therapy for cirrhosis of the liver except for liver transplant. However, finding a compatible liver is difficult due to the low supply and increased demand for healthy livers. Also, after the transplant the patient has to take lot of immunosuppression medicine which also leads to side effects on organ functionality in long run especially kidney. Therefore, finding an alternative therapy for liver cirrhosis patients is crucial and could save thousands of lives per year.

Mesenchymal stem cells (MSCs) are used for autologous stem cell therapy. MSCs have the ability to self-renew and to differentiate into several cell types, including adipocytes, osteocytes, chondrocytes, hepatocytes, neurons, muscle cells, and epithelial cells. MSCs were first identified in the Bone Marrow (BM), they can also be isolated from human umbilical cord blood, synovium, placenta, periosteum, skeletal muscle, and adipose tissue. Of the possible stem cell lines, we chose to use adult MSCs isolated from adipose tissue—adipose-derived stem cells (ADSCs).

ADSCs are similar to BM-derived MSCs in that they can also differentiate into neurogenic, myogenic, osteogenic, and chondrogenic lineages. Moreover, these cells secrete multiple growth factors, including vascular endothelial growth factor, epithelial growth factor, and macrophage colony-stimulating factor. The transplanted ADSCs differentiated into albumin and fetoprotein-secreting liver-like cells one week after transplantation. These results suggest that ADSC transplantation facilitate recovery from chronic liver damage. More importantly, in comparison with other types of adult stem cells, ADSCs are easily accessible and abundant (about 1 × 10^5 ADSCs per gram of fat) ADSC-based stem cell therapy for liver disease is designed to repair diseased hepatocytes and to stimulate endogenous stem cell regeneration.

Doctors at Viecell have developed a standardized protocol that provides autologous human ADSCs Our protocol includes instructions for the isolation and culture expansion of ADSCs, using a minimal amount of starting material from lipo-aspiration

Through the culture expansion process, we can provide a sufficient amount of autologous ADSCs for multiple therapeutic procedures.

Doctors at Viecell has started administering stemcell to the patient of end stage liver disease by giving in Hepatic artery which has given very promising results and cut down the patient recuperation time. This method is very safe for patient and can be done with the use of Catheter.

In summary, intrahepatic stem cell therapy holds great potential for addressing liver diseases and improving patient outcomes.

To Know more about the advance use of Stemcell Therapy doctors can reach out on 9001290028